Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 29, 2021

View Archived Issues

Intratumoral cytokine-encoding mRNA mixture induces antitumor immunity in tumor models

BP-1200_002, a novel anti-CD73 antibody that improves efficacy of cancer immunotherapy

Development of NTC-001, a first-in-class humanized antibody targeting CXCL1

New humanized Col6a1-mutated knock-in mouse model of collagen VI-related muscular dystrophy

Shanghai Zheye Biotechnology divulges G12C mutant GTPase KRAS inhibitors

Peking University presents new boron-carrying agents

Cytomegalovirus DNA polymerase inhibitors discovered at the University of Alberta

New KDM1A inhibitors discovered at Shenyang Pharmaceutical University

Assessing pharmacologic activity of PD(L)-1 MAb therapeutics in tumors by target pharmacodynamics

Targeting KIR3DS1/HLA-F axis as new therapeutic strategy against human adenovirus infections

Intranasal subunit SARS-CoV-2 vaccines elicit mucosal and systemic immunity in vivo

Shionogi licenses S-365598 to ViiV for use in ultra long-acting HIV regimens

Mitochon announces funding to support development of MP-201 for TBI

RARA identified as a druggable target for pediatric acute myeloid leukemia

Point Biopharma reports preclinical data on FAP-alpha inhibitor program

SBIR grant supports Senti's development of CAR-NK cell therapy SENTI-202 for AML

Gamida Cell announces new NK cell construct development programs

Interim data on psilocybin plus NAC in rodent model of mild TBI and PTSD

LG Chem selects preclinical candidate from PD-L1/XT program with Avacta

Close SARS-CoV-2 relative strengthens natural origin theory

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...